Form 8-K - Current report:
SEC Accession No. 0001140361-24-041600
Filing Date
2024-09-23
Accepted
2024-09-23 07:15:36
Documents
14
Period of Report
2024-09-19
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ny20035737x2_8k.htm   iXBRL 8-K 28025
2 EXHIBIT 99.1 ny20035737x2_ex99-1.htm EX-99.1 12813
  Complete submission text file 0001140361-24-041600.txt   181084

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rvnc-20240919.xsd EX-101.SCH 3862
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvnc-20240919_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvnc-20240919_pre.xml EX-101.PRE 16042
16 EXTRACTED XBRL INSTANCE DOCUMENT ny20035737x2_8k_htm.xml XML 4073
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 241314627
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)